BRPI0916366B1 - Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma - Google Patents

Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma Download PDF

Info

Publication number
BRPI0916366B1
BRPI0916366B1 BRPI0916366-2A BRPI0916366A BRPI0916366B1 BR PI0916366 B1 BRPI0916366 B1 BR PI0916366B1 BR PI0916366 A BRPI0916366 A BR PI0916366A BR PI0916366 B1 BRPI0916366 B1 BR PI0916366B1
Authority
BR
Brazil
Prior art keywords
antibody
seq
variable part
heavy chain
light chain
Prior art date
Application number
BRPI0916366-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans-Ulrich Demuth
Stephan Schilling
Martin Kleinschmidt
Kathrin Gans
Anita Reisenauer-Schaupp
Jens-Ulrich Rahfeld
Sonja Kampfer
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of BRPI0916366A2 publication Critical patent/BRPI0916366A2/pt
Publication of BRPI0916366B1 publication Critical patent/BRPI0916366B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916366-2A 2008-07-21 2009-07-10 Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma BRPI0916366B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8230908P 2008-07-21 2008-07-21
DE61/082,309 2008-07-21
PCT/EP2009/058803 WO2010009987A2 (en) 2008-07-21 2009-07-10 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
BRPI0916366A2 BRPI0916366A2 (pt) 2018-05-29
BRPI0916366B1 true BRPI0916366B1 (pt) 2021-08-10

Family

ID=41059893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916366-2A BRPI0916366B1 (pt) 2008-07-21 2009-07-10 Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma

Country Status (15)

Country Link
US (3) US8058405B2 (enExample)
EP (4) EP3338795A1 (enExample)
JP (2) JP5828762B2 (enExample)
KR (1) KR101706789B1 (enExample)
CN (2) CN102131519B (enExample)
AU (1) AU2009273387B9 (enExample)
BR (1) BRPI0916366B1 (enExample)
CA (1) CA2731044C (enExample)
EA (1) EA028427B1 (enExample)
HK (1) HK1222397A1 (enExample)
IL (1) IL210225A (enExample)
MX (1) MX2011000875A (enExample)
NZ (1) NZ590563A (enExample)
WO (1) WO2010009987A2 (enExample)
ZA (1) ZA201100178B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
CN103459421B (zh) * 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
PL3333195T3 (pl) 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
WO2015154091A1 (en) * 2014-04-04 2015-10-08 Lee Yueh Jung Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
US9714953B2 (en) 2014-04-04 2017-07-25 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
CN108136008A (zh) 2015-07-15 2018-06-08 华盛顿大学 针对具有末端GlcNAcβ残基的肿瘤相关复合N-聚糖的抗体及其使用方法
CA2992386A1 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
TW201827467A (zh) * 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI705975B (zh) 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3521308B1 (en) * 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
MA55491A (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
US20230151069A1 (en) 2020-03-10 2023-05-18 Lifearc Cyclic Peptides
EP4185599A4 (en) * 2020-07-22 2024-08-28 Fog Pharmaceuticals, Inc. STAPLED PEPTIDES AND RELATED USES
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
AU2022376940A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
AU2022376930A1 (en) 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
TW202607032A (zh) 2024-06-20 2026-02-16 瑞典商生物極公司 雙特異性結合分子
CN121324641B (zh) * 2025-12-15 2026-04-21 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种检测内罗毕羊病病毒的试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005500389A (ja) * 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
JP4806628B2 (ja) * 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
NZ568459A (en) * 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
MX2008007477A (es) 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
WO2008060364A2 (en) 2006-10-02 2008-05-22 Ac Immune S.A Humani zed antibody against amyloid beta
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2091945B1 (en) 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US7741354B2 (en) 2006-11-09 2010-06-22 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (ja) * 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
DK2160389T3 (da) 2007-04-18 2014-06-23 Probiodrug Ag Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
US8227498B2 (en) 2007-04-18 2012-07-24 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128986A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
WO2008128984A1 (en) 2007-04-20 2008-10-30 Probiodrug Ag Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
AU2008297070A1 (en) 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
WO2009133553A1 (en) * 2008-04-29 2009-11-05 Sandisk Il Ltd. Non-volatile multilevel memory with adaptive setting of reference voltage levels for program, verify and read

Also Published As

Publication number Publication date
JP2011528561A (ja) 2011-11-24
KR20110031989A (ko) 2011-03-29
CN105481980A (zh) 2016-04-13
US8058405B2 (en) 2011-11-15
NZ590563A (en) 2012-06-29
JP6307483B2 (ja) 2018-04-04
US20120064547A1 (en) 2012-03-15
EP3047854A1 (en) 2016-07-27
BRPI0916366A2 (pt) 2018-05-29
CA2731044A1 (en) 2010-01-28
MX2011000875A (es) 2011-04-05
US20160053001A1 (en) 2016-02-25
EA201100231A1 (ru) 2011-08-30
AU2009273387A1 (en) 2010-01-28
EP2320942A2 (en) 2011-05-18
EP3338795A1 (en) 2018-06-27
KR101706789B1 (ko) 2017-02-14
ZA201100178B (en) 2012-02-29
HK1222397A1 (zh) 2017-06-30
CA2731044C (en) 2020-07-14
US9156907B2 (en) 2015-10-13
AU2009273387B2 (en) 2014-12-04
EP3338796A1 (en) 2018-06-27
WO2010009987A3 (en) 2010-05-20
CN102131519B (zh) 2016-01-13
EA028427B1 (ru) 2017-11-30
US20100021478A1 (en) 2010-01-28
US9676843B2 (en) 2017-06-13
WO2010009987A2 (en) 2010-01-28
CN102131519A (zh) 2011-07-20
EP3047854B1 (en) 2018-03-21
HK1158946A1 (zh) 2012-07-27
EP2320942B1 (en) 2018-03-14
IL210225A0 (en) 2011-03-31
AU2009273387B9 (en) 2015-06-11
IL210225A (en) 2015-09-24
JP5828762B2 (ja) 2015-12-09
JP2016028064A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
JP5828762B2 (ja) 診断用抗体アッセイ
US9657089B2 (en) Diagnostic antibody assay
EA038120B1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
HK1158946B (en) Diagnostic antibody assay
HK1192568B (en) Diagnostic antibody assay
NZ614217B2 (en) Diagnostic antibody assay
HK1192568A (en) Diagnostic antibody assay

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS AG (DE)

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS N.V. (DE)